

Following is the CPDD policy for disclosure of potential conflicts of interest for those making Oral or Poster Presentations. For an oral presentation, the second slide should contain the disclosure. For a poster presentation, the disclosure should be put on the poster board. Please read the following policy and note the samples at the end of the document.

COLLEGE ON PROBLEMS OF DRUG DEPENDENCE

POLICY ON DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST IN MEETING PRESENTATIONS SPONSORED BY THE COLLEGE ON PROBLEMS OF DRUG DEPENDENCE

Adopted by the Board of Directors, June 17, 2006

The College on Problems of Drug Dependence (CPDD) requires any individual who is an author on a presentation at a CPDD-sponsored event to make a conflict-of-interest disclosure for that presentation in accordance with the requirements stated below.

Content of Disclosure Requirement

Each author on an oral or poster presentation at the annual meeting or any other meeting convened under the auspices of the CPDD is required to disclose--

- 1) the source of any funding that supported, in whole or in part, the research or writing to which the presentation relates;
- 2) any financial interest (see definition at the end of this policy) held, at the time of the presentation or within the preceding 24 months, by the author or by his or her spouse (or legal equivalent) in a drug, device, or procedure to which the topic of the presentation relates;
- 3) any employment, consultant, directorship, partnership, advisory, or other professional relationship at the time of the presentation or within the preceding 24 months between the author or his or her spouse (or legal equivalent) and any business entity, research organization, or educational institution with a proprietary or pecuniary interest in a drug, device, or procedure to which the topic of the presentation relates; and
- 4) any gifts, meals, or reimbursements of expenses, with a combined monetary value of U.S. \$100 or more, received within the preceding 24 months from any one business entity, research organization, or educational institution with a proprietary or pecuniary interest in a drug, device, or procedure to which the topic of the presentation relates.

The disclosure policy does not require an author to disclose--

- 1) the value of a pecuniary interest; or
- 2) the terms, conditions, or compensation associated with any professional relationship between an author or his or her spouse (or legal equivalent) and any entity, research organization, or educational institution.

Time and Format of the Disclosure

The disclosure required by the policy is to be made at the time of the presentation in a form or manner that is accessible to any person viewing or hearing the presentation.

The format of the disclosure shall be the same as, or consistent with, the format of the presentation as described below.

- 1) For oral presentations, the slide after the title slide shall contain the disclosure information in an easily readable format. This slide should be displayed for a minimum of 10 seconds if it contains any disclosures other than the source(s) of the funding for the research.
- 2) For poster presentations, the disclosure information shall be incorporated into the poster or placed on the poster board with the poster for the duration of the poster exhibition.
- 3) Level of detail regarding each financial interest is left to each author to decide. See sample disclosure statements.

Definitions

Financial interest.--The term "financial interest" means a proprietary interest in (1) a *profit or nonprofit organization*, (2) the ownership of *stock or stock options* in a corporation, (3) a *partnership interest* (whether or not limited) in a partnership, (4) an ownership interest in a *joint venture*, (5) an interest as a grantor or beneficiary of a *trust* (including a *blind trust*), (6) a *patent*, or (6) *any other direct or indirect* investment in an enterprise that could receive financial benefit from the drug, device, or procedure ***to which a presentation relates***.

This definition does not include derivative investment attributable to investment in a publicly available *mutual fund, trust, or other pooled investment fund* the holdings of which are diversified among multiple investments that are not all related to the drug, device, or procedure to which the presentation relates.

Presentation.--The term presentation means an address, poster, or other presentation of the results of research or other study or investigation; a review of research findings, studies, or investigations; and any other activity determined by the Board of Directors of CPDD to constitute a presentation for purposes of this policy.

Sample Disclosures

Reminders:

Disclosures are required only for financial interests that relate to the topic of the presentation.

Disclosures are required only for financial interests held at the time of the presentation or in the preceding 24 months.

Only the fact of the financial interest or relationship is required. Providing further detail is at the discretion of each author if he or she wishes to do so.

Other acknowledgement of support for the research may be made on the same slide.

Sample: Simplest form.

***Panacea, a New Drug for the Long-term Treatment of Cocaine Craving
by R.E. Searcher, S.R. CoAuthor, and J.R. CoAuthor***

The authors have no financial relationships that related to the topic of this presentation.

Or

Financial relationships that relate to the topic of this presentation:

Dr. Searcher: Wave of the Future Pharmaceuticals, Silver Bullet Biotechnology

Dr. S.R. CoAuthor: One-Day-at-a-Time Drug Treatment Cooperative

Dr. J.R. CoAuthor: None

More detail on the nature of the relationship may be provided if an author prefers to do so.

Examples:

Dr. Searcher: Consultant, Wave of the Future Pharmaceuticals; stock holdings, Silver Bullet Biotechnology

Dr. S.R. CoAuthor: former president, One-Day-at-a-Time Drug Treatment Cooperative

Dr. J.R. CoAuthor: None

Similarly more detail on the value of the relationship may be provided if the author prefers

Examples: stock in Silver Bullet Biotechnology (<100 shares)